白介素-33在急性呼吸窘迫综合征中的研究进展

Research progress of interleukin-33 in acute respiratory distress syndrome

急性呼吸窘迫综合征（acute respiratory distress syndrome,ARDS）是以顽固性低氧血症和进行性呼吸困难为主要临床特点的综合征,是危重症患者死亡的主要原因之一。尽管,近年来医疗技术的迅猛发展和新的药物的应用使ARDS的预后有所改善,但其病死率仍高达40%~50%。因此,更充分的了解ARDS的发病机制,实现早期诊断,为临床上ARDS的防治提供指导仍是呼吸和重症医学界研究的重点和热点。白介素（interleukin,IL）-33是新近发现的IL-1家族成员,在炎症、感染、自身免疫性疾病等多种疾病中发挥重要的警报素作用,促进机体的炎症反应,加重机体组织的损伤。故IL-33及其信号通路可能成为阻断炎症通路的级联反应的一个潜在的分子靶点。本文就IL-33在ARDS中的研究进展做一综述。

Acute respiratory distress syndrome（ARDS）is a clinical syndrome characterized by refractory hypoxemia and progressive dyspnea. It is one of the leading causes of death in critically illed patients. In recent years,although the rapid development of medical technology and the application of new drugs have improved the prognosis of ARDS,the mortality of ARDS is still as high as 40%-50%. Therefore,it is still the focus and hotpot in the research of respiratory and intensive medicine to further understand the pathogenesis of ARDS,achieve early diagnosis,and provide guidance for the prevention and treatment of ARDS. Interleukin-33（IL-33）is a recently discovered member of the Interleukin-1（IL-1）family. It plays a crucial role as an alarmins in inflammation,infection,au toimmune disease and many other diseases,enlarges the body＇s inflammatory response,and aggravate tissue injury. Therefore,IL-33 and its signal pathway probably become potential molecular targets to block the cascade of inflammatory pathways in the treatment of ARDS. In this paper,we reviewed on the role of IL-33 in ARDS.